03.09.18
WuXi Biologics and Adagene Inc., an emerging biotech company developing antibody therapeutics, entered a strategic collaboration to support supply of Adagene's products for clinical trials under Investigational New Drug (IND) applications in both China and the U.S. Adagene has an internal pipeline of antibody therapeutics focused on difficult antigens, and therapeutic candidates with enhanced biophysical properties.
"The strategic collaboration with WuXi Biologics will enable Adagene to focus on our core competency in the discovery of novel antibody therapeutics and by leveraging the process development and manufacturing capabilities of WuXi Biologics will accelerate Adagene's next wave of innovative products into the clinic," said Dr. Peter Luo, co-founder and chief executive officer of Adagene.
"We are pleased to work closely with Adagene in developing and manufacturing some urgently-needed antibody therapeutics through the world-class, high-quality biologics platform at WuXi Biologics," said Dr. Chris Chen, chief executive officer of WuXi Biologics. "The collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, and then benefit patients around the world."
"The strategic collaboration with WuXi Biologics will enable Adagene to focus on our core competency in the discovery of novel antibody therapeutics and by leveraging the process development and manufacturing capabilities of WuXi Biologics will accelerate Adagene's next wave of innovative products into the clinic," said Dr. Peter Luo, co-founder and chief executive officer of Adagene.
"We are pleased to work closely with Adagene in developing and manufacturing some urgently-needed antibody therapeutics through the world-class, high-quality biologics platform at WuXi Biologics," said Dr. Chris Chen, chief executive officer of WuXi Biologics. "The collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, and then benefit patients around the world."